Quote:In April 2017, anti-vaccine groups seemed to have finally gotten what amounted to the Holy Grail for their cause: an allegedly large-scale, peer-reviewed study showing the links between vaccines and autism among a large population of children.
Vaccine skeptic groups, who reject the wide body of scientific literature refuting that link between vaccines and autism, have long sought such a study, but they’ve been hampered by practical concerns, most notably the ethical implications of withholding vaccines from a large group of children.
Released to heavy promotional fanfare on anti-vaccine websites and social media, a 24 April 2017 study published by the Journal of Translational Science claimed to be that Grail. The study (titled “Pilot Comparative Study on the Health of Vaccinated and Unvaccinated 6- to 12-Year Old U.S. Children”) neatly solved the problem of withholding vaccines by surveying parents who had already chosen not to vaccinate their children.
Using an online survey of 415 mothers of homeschooled children, the study concluded that vaccines can increase the risk of neurological developmental disorders, particularly in cases of preterm birth.
The anti-vaccine website Age of Autism, which also helped raise money for the study, reported its findings in glowing terms:
As parents have long expected, the rate of autism is significantly higher in the vaccinated group, a finding that could shake vaccine safety claims just as the first president who has ever stated a belief in a link between vaccines and autism has taken office.
The only problem? The paper is a identical version of a paper briefly published in Frontiers in Public Health in 2016 before being disowned by the publisher. This Translational Science version, as well, was pulled from the website with some reports that it had been retracted as well. As of 18 May 2017, however, the study reappeared on that journal’s website with no public comment for why it was removed or returned.
https://www.snopes.com/news/2017/05/17/vaccine-study-autism/
As we will describe below, these de facto retractions and high level of scrutiny stem not from a conspiracy to silence work critical of the medical establishment, but from the myriad ethical, methodological, and quantitative problems inherent in the study and to the research group behind it.
In short, the study’s design was flawed from the start.
Problems With The Study’s Statistical Analyses
The authors then dressed up their flawed, potentially biased data set in the cheap Halloween costume of a statistically responsible study. No amount of statistics, however, will get around the fact that there were not enough people in the study to address the questions they claim to have investigated.
Only 47 children in the 666-person study had what the authors defined as a neurological developmental disorders (also called an NDD), an already broadly-defined category that includes multiple conditions. Despite this, viral blog posts reporting on this study repeatedly state that autism risk, specifically, was higher in the vaccinated population. What those headlines fail to convey is that such a claim rests entirely on the nine people in the study who were actually diagnosed with autism.
The grossly insufficient sample size is most apparent in the lack of precision in the final results. The authors use something called an “odds ratio” to present their analysis — a measure that compares the relative odds of two populations with differing medical histories (i.e. vaccinated versus unvaccinated) developing a certain medical condition (i.e. NDDs). When scientists use odds ratios, they give a measure of how precise the odds are — a range of uncertainty that can be thought of as, essentially, as a margin of error.
In the Mawson study, they claim (for example) that a preterm birth combined with a vaccination caused a 6.6-fold increase in the odds of a neurological condition or learning disability. This result, a remarkably large odds ratio, comes with a laughable amount of precision — a range from 2.8 to 15.5. That wide a range of possibility is a big red flag, and is representative of many of the associations documented in the study.
The reason there is a range of possible outcomes is because odds ratios are generally pushed through statistical models meant to untangle the competing influences of other factors in their data, isolating the specific effect of one risk factor on an outcome. This is a crucial step for Mawson et al, because a significant number of children included in the NDD pool were also born prematurely, which multiple studies have already robustly linked to NDDs.
The competing influence of preterm birth on NDDs is arguably the largest methodological hurdle for the researchers to get around. The authors needed to make crystal clear that the association between NDDs and vaccination holds without the influence of preterm birth, or else the study is meaningless. They claim to have done so, but provide next to no documentation on the specifics of that process.
Without explaining what they did exactly, they simply write that they used two statistical models to adjust for preterm birth and that the “second adjustment” showed that there was a) no relationship between preterm birth and NDDs and b) there remained a relationship between vaccination and NDDs.
That is quite a statement. The researchers’ claim that there is no association between preterm birth and NDDs flies in the face of long-established science linking the two. Anytime research that contradicts long-understood and scientifically documented relationships should be read with a critical eye toward the methods used. But that is almost impossible here, as the only documentation the authors offer of their methods is to say they carried out a variety of regressions using a statistical software program called SAS.
What makes this worse is that the authors did not explicitly offer a hypothesis or any statistical criteria prior to beginning the study. That makes their data vulnerable to confirmation bias, as it allows them to potentially slice and dice data in as many ways as they want and plug those data into a program to see if their desired results that pops out. This study’s small sample size undoubtedly compounds this possibility, as it increases the likelihood for chance associations that may be flashy, but are ultimately not reproducible.
In April 2017, anti-vaccine groups seemed to have finally
Top 10 Most Recent News Articles
Innovent's IBI354: New Data Spurs Hope for HER2+ BC
Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...
Continue Reading
Fluence Energy Hits Legal Snag: Investors Called to Act
Fluence Energy Faces a Securities Fraud Challenge It's like watching a slow-motion train wreck. Fluence Energy, Inc. (NASDAQ: FLNC) now finds itself in the crosshairs of a securities fraud class action lawsuit. Apparently, someone was playing fast and loose with the truth concerning their financial guidance. The period in question stretches from November 24, 2025, to...
Continue Reading
TORRAS Cases Balance Protection with Slim Design for 2026
Are Slim iPhone Cases Really Protecting Your Investment? Anyone who's dropped a brand-new phone knows the pain of watching your investment smack the concrete. But hey, welcome to 2026, where Consumer365's latest rundown on iPhone protective gear turns the spotlight on TORRAS. These folks grabbed attention with their Q3 Air and Q3 Air Pro cases, crafted for iPhone 18 Pro...
Continue Reading
D-Wave Investors Must Decide by Dec 15 Class Suit
Facing the Class Action Deadline There's nothing like a looming deadline to stir the pot, and that's exactly what's happening with D-Wave Quantum Inc. (NASDAQ: QBTS) as it faces the heat of a class action lawsuit. Investors who got caught in the slide between February 26, 2026, and August 25, 2026, need to sharpen their pencils and mark December 15, 2026, on their...
Continue Reading
BAIC FOTON Eyes African Market with Strategic Moves
Revving Up for Africa Alright, gearheads and number-crunchers, strap in. BAIC FOTON is making headlines again, and this time they’re zooming right into Africa—like they're claiming pole position on a circuit that's been ignored by many. They’re calling it a “Drive to Great!” but what does that mean for us investors who aren’t just in it for the entertainment?...
Continue Reading
LexisNexis Debuts AI-Guided Field Clarity at IACP 2026
LexisNexis Takes a Serious Step Forward The world of law enforcement reporting just got a shake-up. LexisNexis Coplogic Solutions launched a souped-up version of its Desk Officer Reporting System (DORS) at the IACP 2026 event. They paired DORS with Field Clarity, a newfangled AI-powered assistant that aims to make police reporting slicker and more accurate. You can bet...
Continue Reading
Gildan Activewear Faces Legal Battle Over Alleged Fraud
Investor Alert: Gildan's Legal Showdown Alright, here's a twist you didn't see coming—or maybe you did if you've been tracking the ticker tapes like a hawk. Gildan Activewear Inc. (NYSE:GIL) is stuck in the kind of hot water that can scald the bottom line. The Stakes: Racing Towards December 14 Marked on your calendar, December 14, is a date of some significance if...
Continue Reading
DigitalXForce Shakes Up GRC: AI-Infused X-ROC Launch
Turning Risk Management on Its Head Well, here's a company not just tinkering around the edges but flipping the script on Governance, Risk, and Compliance (GRC) with their latest rollout: DigitalXForce and its X-ROC. Yeah, it's yet another acronym to juggle, but don't roll your eyes just yet. This AI-driven beast isn't about occasional boardroom reports. No sir, it's a...
Continue Reading
Lilly's Olomorasib: New Data Sparks Hope for G12C NSCLC
New Data Unveiling Potential Shifts in NSCLC Treatment Man, if there's one thing the oncology world craved, it's progress against KRAS G12C-mutant non-small cell lung cancer (NSCLC). We're talking about a challenge as tough as a two-dollar steak. But hey, Eli Lilly's (NYSE:LLY) putting some serious cards on the table with olomorasib, and folks at the ESMO 2026 Congress...
Continue Reading
Ivonescimab Promises New Hope for Advanced BTC Patients
Shifting the Paradigm in Biliary Tract Cancer Treatment Here's the scoop from the bustling world of oncology: the trial of Ivonescimab plus chemotherapy is stirring waves among experts in advanced biliary tract cancer (BTC). Contrary to the usual drowsy mornings with coffee and market pages, this data from Hong Kong wasn't about Wall Street this time. This trial might...
Continue ReadingTop 5 Most Recently Viewed Articles
Revolutionizing Software Development with Agentic AI Features
Progress Software Unveils New AI Features in Telerik and Kendo UI Progress Software is leading the way in enhancing application development with its latest update to Telerik and Kendo UI. This innovative release introduces groundbreaking agentic capabilities designed to empower developers with advanced tools for building enterprise-grade applications efficiently. With...
Continue Reading
Hao Pan's Share Transactions Reveal Insights at Orion Corporation
Insights into Recent Share Transactions at Orion Corporation Orion Corporation actively engages in managing its share transactions, reflecting transparency and accountability within its operations. Recently, a significant disclosure involving Hao Pan, a senior manager at Orion Corporation, was shared under the guidelines of the Market Abuse Regulation. Who is Hao Pan? Hao...
Continue Reading
Analyzing Toast's Market Performance and Investor Sentiment
Understanding Toast's Market Movements Toast Inc (NYSE: TOST) has recently seen a noticeable increase in the short percent of its float, which has risen to 9.06% compared to previous reports. This increase reflects a significant amount of activity, with approximately 32.58 million shares sold short. This statistic translates to 6.62% of all shares actively available for...
Continue Reading
Anthony Scaramucci Shares Insights on Memecoins and Digital Assets
Scaramucci's View on Memecoins Renowned financial expert, Anthony Scaramucci, founder of SkyBridge Capital and an advocate for cryptocurrency, has made headlines with his bold predictions regarding the future of memecoins. He believes that the trajectory of these digital assets is likely set towards a decline. Limited Utility of Memecoins Identifying the Risks During a...
Continue Reading
Strengthening China-Africa Partnerships for a Shared Future
Strengthening China-Africa Partnerships for Progress Recently, Chinese President Xi Jinping hosted a banquet attended by dignitaries from Africa and around the world, celebrating the strong ties between China and Africa. This event highlighted a shared commitment to building a community with a common future, showcasing how these two regions are collaborating for mutual...
Continue Reading